Targeting metabolic dysregulation for fibrosis therapy

Area of Science:

• Biochemistry
• Pathology
• Pharmacology

Background:

• Fibrosis involves abnormal extracellular matrix deposition, leading to organ dysfunction and significant disease burden.
• Current therapeutic options for preventing or reversing fibrosis are limited.
• Metabolic alterations are increasingly recognized as a key pathogenic driver of fibrosis in multiple organs.

Purpose of the Study:

• To review current evidence on the role of metabolic alterations in fibrosis.
• To explore novel opportunities for developing drugs targeting metabolic reprogramming for fibrosis reduction.
• To discuss challenges and potential utility of these antifibrotic strategies.

Main Methods:

• Literature review of studies investigating metabolic pathways in fibrosis.
• Analysis of antifibrotic drug development targeting metabolic processes.
• Synthesis of evidence on metabolic reprogramming for therapeutic intervention.

Main Results:

• Metabolic alterations are integral to fibrotic pathogenesis across diverse organs.
• Antifibrotic drugs in development often target pathways with metabolic implications.
• Metabolic reprogramming presents a viable strategy for novel antifibrotic drug discovery.

Conclusions:

• Targeting metabolic pathways offers a promising avenue for developing novel antifibrotic therapies.
• Further research into metabolic reprogramming holds potential for treating a wide range of fibrotic diseases.
• Metabolically targeted therapies could address the unmet need for effective fibrosis treatments.